任意の製品分析
許可いただいた場合、プライバシーに配慮した限定的な分析を使用し、どのリサーチ経路が有効かを把握します。広告トラッカーやセッション録画は使用しません。この選択は設定で変更できます。詳しくは プライバシーポリシー.
Mettler-Toledo International Inc.'s published Sell conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $30.9B | |
|---|---|---|
| Revenue (ttm) | 4.1B | |
| Net income (ttm) | 905.6M | |
| EPS (ttm) | $44.4 | |
| Shares out | 20M | |
| P/E (trailing) | 38.2x | |
| P/E (forward) | 28.5x | |
| Volume | 128,542 | |
| Beta | 1.19 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $3.72B | $3.92B | $3.79B | $3.87B | $4.03B | +2.0% |
| Gross profit | $2.17B | $2.31B | $2.24B | $2.33B | $2.39B | +2.4% |
| Operating income | $994.7M | $1.13B | $1.15B | $1.13B | $1.12B | +3.0% |
| Net income | $769.0M | $872.5M | $788.8M | $863.1M | $869.2M | +3.1% |
| EPS (diluted) | $32.78 | $38.41 | $35.90 | $40.48 | $42.05 | +6.4% |
| EBITDA | $1.10B | $1.24B | $1.15B | $1.25B | $1.24B | +3.1% |
| R&D | $169.8M | $177.1M | $185.3M | $189.4M | $199.4M | +4.1% |
| SG&A | $944.0M | $938.5M | $904.1M | $936.3M | $998.3M | +1.4% |
Recent company headlines from major financial publishers.
Revenue compounds at 4.5%-5.1% annually, supported by steady 200 bps pricing realization and gradual recovery in Chinese operations, while Western European and US operations sustain mid-single digit cash generation,. Operating margins normalize around 28.1% to 28.7%, and free cash flow generation exceeding $840M supports ongoing annual share count reductions.
Chinese demand inflects positively on government stimulus transmission and replacement cycles, while biopharmaceutical laboratory capex accelerates as interest rates ease. Consolidated organic revenue growth accelerates to 6.5%-7.5% annually, operating margins expand toward 29.5% via operating leverage and SternDrive productivity, and sustained share buybacks drive compounded EPS growth above 12%.
| Ke ↓ / g → | 2.5% | 2.8% | 3.0% | 3.3% | 3.5% |
|---|---|---|---|---|---|
| 8.5% | $979 | $1,008 | $1,039 | $1,073 | $1,112 |
| 9.0% | $910 | $933 | $959 | $987 | $1,017 |
| 9.5% | $850 | $870 | $891 | $914 | $939 |
| 10.0% | $799 | $815 | $833 | $852 | $873 |
| 10.5% | $753 | $767 | $782 | $799 | $816 |
Upcoming earnings date and setup when available.
各月に公開されたリサーチ版が示したレーティングです。レーティングは分析時点の株価を公正価値と比較したもので、判断が当たったかどうかの記録ではありません。
| 年 | 1月 | 2月 | 3月 | 4月 | 5月 | 6月 | 7月 | 8月 | 9月 | 10月 | 11月 | 12月 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |